Latest revenue
$3.3M
as of 2025-12-31
Latest net income
$-33.8M
as of 2025-12-31
Net margin
-1018.3%
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ALDX is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $97.7M
- Enterprise value
- $79.2M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 2.32×
- Dividend yield
- 0.0%
- 52-wk high
- $6.17
- 52-wk low
- $1.07
- Beta
- —
- Shares out
- 60.3M
5-year trend
What this company does
ITEM 1. BUSINESS Overview Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-248, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye…
AI summary unavailable — showing raw filing excerpt
Generated from ALDX's filing dated 2026-02-27
Key risks
ITEM 1A. Risk Factors. Our business is subject to numerous risks. You should carefully consider the risks described below together with the other information set forth in this annual report on Form 10-K, which could materially affect our business, financial condition, and future results. The risks described below are not the only risks facing our company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, prospects, financial condition, and operating results. Summary of Risks Related to our Business Below is a summary of the principal factors that make an investment in our common stock speculative…
AI summary unavailable — showing raw filing excerpt
Generated from ALDX's filing dated 2026-02-27
Profitability
Operating margin
-1061.0%
9.3%Net margin
-1018.3%
12.9%Return on equity
-76.5%
2.8%Return on assets
-47.0%
12.0%Leverage
Debt / equity
0.63×
32.8%Long-term debt / equity
0.00×
100.0%Debt / assets
38.6%
20.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-3.5M | +65.2% | — |
Q4 2025 2025-12-31 | — | — | $-6.5M | +59.1% | — |
Q3 2025 2025-09-30 | — | — | $-7.7M | +49.1% | — |
Q2 2025 2025-06-30 | — | — | $-9.8M | +42.0% | — |
Q1 2025 2025-03-31 | — | — | $-9.9M | -22.9% | — |
Q4 2024 2024-12-31 | — | — | $-15.8M | — | — |
Q3 2024 2024-09-30 | — | — | $-15.1M | -84.6% | — |
Q2 2024 2024-06-30 | — | — | $-16.8M | -87.5% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ALDX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$118.3K
Insider selling
$113.7K
Net activity
+$4.6K
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ALDX
Institutional value
$19.1M
Total shares held
12.4M
Distinct holders
70
-64 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3.8M | $6.4M | -86.2K (-2.2%) | Trimmed |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2.4M | $4.0M | — | New |
| 3 | JANE STREET GROUP, LLC | 968.9K | $1.6M | +665.0K (+218.9%) | Added |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 807.8K | $1.4M | — | New |
| 5 | DIMENSIONAL FUND ADVISORS LP | 624.2K | $1.1M | +11.9K (+1.9%) | Added |
| 6 | UBS Group AG | 537.6K | $908.5K | +441.9K (+461.9%) | Added |
| 7 | VANGUARD FIDUCIARY TRUST CO | 338.6K | $572.3K | — | New |
| 8 | WOODSTOCK CORP | 266.8K | $450.8K | +0 (+0.0%) | No change |
| 9 | WELLS FARGO & COMPANY/MN | 189.7K | $320.6K | -176.4K (-48.2%) | Trimmed |
| 10 | Invesco Ltd. | 169.7K | $286.8K | +6.6K (+4.1%) | Added |
| 11 | Bank of New York Mellon Corp | 136.7K | $231.1K | +21.0K (+18.1%) | Added |
| 12 | KENNEDY CAPITAL MANAGEMENT LLC | 95.9K | $162.0K | -1.2M (-92.4%) | Trimmed |
| 13 | Mariner, LLC | 91.9K | $155.3K | +69.0K (+301.6%) | Added |
| 14 | FOX RUN MANAGEMENT, L.L.C. | 91.0K | $152.8K | +70.0K (+333.5%) | Added |
| 15 | Russell Investments Group, Ltd. | 84.3K | $142.5K | -29.8K (-26.1%) | Trimmed |
| 16 | RHUMBLINE ADVISERS | 69.2K | $116.9K | -1.2K (-1.7%) | Trimmed |
| 17 | STRS OHIO | 68.2K | $115.3K | +0 (+0.0%) | No change |
| 18 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 61.1K | $101.4K | +28.4K (+86.9%) | Added |
| 19 | DEUTSCHE BANK AG\ | 50.3K | $85.0K | -267.1K (-84.2%) | Trimmed |
| 20 | INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | 37.4K | $62.8K | -10.1K (-21.3%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ALDX's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.